# Validating a Multibiomarker Panel for the Assessment of Quantity and Quality of Plant Foods in the Diet (PLAENTI): Protocol for a Parallel Group–Designed Randomized Controlled Trial

**Authors:** Victor Schmalle, Julia Renz, Paola G Ferrario, Stephanie Seifert, Ann Katrin Engelbert, Oliver Wittek, Benedikt Merz, Lorraine Brennan, Claudine Manach, Manuela J Rist, Achim Bub

PMC · DOI: 10.2196/77571 · JMIR Research Protocols · 2026-02-27

## TL;DR

This study validates a multibiomarker panel to objectively measure the quantity and quality of plant foods in diets using blood, urine, and stool samples.

## Contribution

The study introduces a novel multibiomarker panel for accurate dietary assessment of plant foods through a controlled trial.

## Key findings

- A multibiomarker panel was developed to assess plant food intake objectively.
- The trial successfully collected biological samples from 59 participants for biomarker analysis.
- The study design included controlled dietary interventions to validate biomarker responses.

## Abstract

Although a high intake of plant foods is often considered healthy, some plant foods can be detrimental to health. Reliable dietary assessment is crucial to examine the relationship between diet and disease. Current dietary assessment methods rely on self-reported intake data, which are subject to bias. Objective measurement using biomarkers of food intake could mitigate this problem. However, single biomarkers of food intake have limitations as well. Combining several biomarkers of food intake into a multibiomarker panel could attenuate these limitations and allow for an accurate, objective dietary assessment.

The PLAENTI study aims to validate a multibiomarker panel for the assessment of quantity and quality of plant foods in the diet.

PLAENTI is a randomized controlled trial with 4 arms in a parallel design. Metabolically healthy adults (≥18 years old) were enrolled in the study. The study consisted of 1 week of run-in, with a standardized diet low in healthful plant foods for all participants; 2 weeks of a dietary intervention according to the assigned arm; and 1 week of washout, during which participants returned to their habitual diet. During the intervention, the participants’ diet consisted of either a low, medium, or high proportion of healthful plant foods or a high proportion of unhealthful plant foods in the diet according to the assigned arm. The arm that received a high proportion of healthful plant foods served as the control. All food was provided based on energy-adjusted menu plans. During the visits, anthropometry and body composition were assessed, and blood samples were collected. Throughout the study, participants collected multiple urine samples (24-hour urine, evening and morning spot urine) and stool samples. Blood and urine samples will be analyzed by liquid chromatography-mass spectrometry to determine biomarker levels for the validation of a multibiomarker panel.

After receiving approval from the ethics committee, recruitment began, and the first screening visit took place in November 2023. Between January and August 2024, of the 66 enrolled participants, 59 (31 female, 28 male) successfully completed the study, and their urine, blood, and stool samples are available for analysis. PLAENTI was conducted in 5 waves with a maximum of 16 participants enrolled in each wave. The mean age of the study population was 45.5 (SD 18.4) years, the mean BMI was 24.8 (SD-3.9) kg/m², and the mean total energy expenditure was 2464 (SD 440) kcal.

PLAENTI was conducted in a highly controlled and standardized manner, yielding samples and data that will be used to examine whether the quantity and quality of plant foods in the diet can be assessed using a multibiomarker panel. Successful validation of the multibiomarker panel would enable its application for objective dietary assessment.

## Full-text entities

- **Genes:** LRIT1 (leucine rich repeat, Ig-like and transmembrane domains 1) [NCBI Gene 26103] {aka FIGLER9, LRRC21, PAL}, MBP (myelin basic protein) [NCBI Gene 4155], GGT1 (gamma-glutamyltransferase 1) [NCBI Gene 2678] {aka CD224, D22S672, D22S732, GGT, GGT 1, GGTD}
- **Diseases:** flatulence (MESH:D005414), abdominal pain (MESH:D015746), DIT (MESH:D000092582), Alcohol or drug abuse (MESH:D019966), Tumors (MESH:D009369), gastrointestinal symptom (MESH:D012817), HH (MESH:D006432), noncommunicable diseases (MESH:D000073296), diarrhea (MESH:D003967), nausea (MESH:D009325), intolerance (MESH:D005633), nutrient malabsorption (MESH:D008286), Acute or chronic infectious diseases (MESH:D013969), heartburn (MESH:D006356), Allergy (MESH:D004342), constipation (MESH:D003248)
- **Chemicals:** triglycerides (MESH:D014280), bilirubin (MESH:D001663), uric acid (MESH:D014527), EDTA (MESH:D004492), sugar (MESH:D000073893), fat (MESH:D005223), sodium chloride (MESH:D012965), cholesterol (MESH:D002784), vegetable oils (MESH:D010938), lithium (MESH:D008094), water (MESH:D014867), carbohydrate (MESH:D002241), FFQ (-), glucose (MESH:D005947), creatinine (MESH:D003404), HU (MESH:D006918), heparin (MESH:D006493), Alcohol (MESH:D000438), LH (MESH:D007986), lipid (MESH:D008055), polypropylene (MESH:D011126)
- **Species:** Musa acuminata (banana, species) [taxon 4641], Theobroma cacao (cacao, species) [taxon 3641], Malus domestica (apple, species) [taxon 3750], Homo sapiens (human, species) [taxon 9606], Bos taurus (bovine, species) [taxon 9913], Solanum tuberosum (potatoes, species) [taxon 4113]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12954706/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12954706/full.md

## References

62 references — full list in the complete paper: https://tomesphere.com/paper/PMC12954706/full.md

---
Source: https://tomesphere.com/paper/PMC12954706